Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events.
about
C-reactive protein inhibits cholesterol efflux from human macrophage-derived foam cells.Sex hormone modulation of proinflammatory cytokine and C-reactive protein expression in macrophages from older men and postmenopausal women.High-sensitivity C-reactive protein, other markers of inflammation, and the incidence of macular degeneration in womenPrevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational study.Acute vs chronic volume overload on arterial stiffness in haemodialysis patients.C-reactive protein in patients with COPD, control smokers and non-smokersChanges of High Sensitivity C-Reactive Protein During Clopidogrel Therapy in Patients Undergoing Percutaneous Coronary Intervention.Chronic obstructive pulmonary disease: a chronic systemic inflammatory disease.Measurement of the acute inflammatory response to walking exercise in COPD: effects of pulmonary rehabilitation.Vitamin D and risk of CVD: a review of the evidence.High-sensitivity C-reactive Protein and Tumor Necrosis Factor Alpha in Pseudoexfoliation Syndrome.A case-control study on the relationship between HDL2b and non-alcoholic fatty liver disease in Chinese type 2 diabetic patients.Smoking combined with overweight or obesity markedly elevates cardiovascular risk factors.Negatively charged low-density lipoprotein is associated with atherogenic risk in hypertensive patients.Markers for endothelial dysfunction, but not markers for oxidative stress correlate with classical risk factors and the severity of coronary artery disease. (A subgroup analysis from the Ludwigshafen Risk and Cardiovascular Health Study).Dietary factors associated with subclinical inflammation among girls.Inflammatory markers and metabolic syndrome among adolescents.Associations of the Baltic Sea diet with cardiometabolic risk factors – a meta-analysis of three Finnish studies
P2860
Q34082954-E62C3A03-0CBD-4220-9A47-EFDC6B553839Q34196350-4B3E9311-5425-481D-9951-E910314E1D4FQ34565911-35D89F45-E345-401E-9BA2-5166A2BDC646Q35834883-D995B745-182E-449B-9A7F-BA972B0B3FF4Q36066976-D240E991-7EA6-477E-93B3-B928320D7F7DQ36148673-28AF96C4-C9EB-48F6-9AAB-8A100AB0531CQ36569257-2904F305-71BC-4C69-8F76-1086032A1884Q37016623-BB36F91F-C6FD-4150-AAAC-4A444D5FAC43Q37224514-4002156C-3397-4737-A054-4771F24C769BQ38361922-429CB20C-3ACB-4EED-8B17-E1AF458B74DCQ43143286-94C43FDD-C86A-4A7E-9735-358F8A66F9F2Q43281335-27DD6D16-4CAE-4BF9-9101-B4C55B90B76FQ43717535-A59EFB2C-8D76-4045-A346-8F8AD2979CE7Q44229858-9F655E05-A78B-4DA7-86C7-F5DD20CC2FFEQ50719651-93BB27A1-9FCF-412B-9714-60AF76AD25E5Q51332403-ACAC29DC-7BDF-4AF6-9D3B-96F857F531A9Q51352565-6C6B67A9-9586-4282-95AD-EEE54E827F6CQ57303247-5F6AEBDF-8FFF-4476-9D52-7E3F04FB7116
P2860
Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Clinical use of high sensitivi ...... adverse cardiovascular events.
@ast
Clinical use of high sensitivi ...... adverse cardiovascular events.
@en
type
label
Clinical use of high sensitivi ...... adverse cardiovascular events.
@ast
Clinical use of high sensitivi ...... adverse cardiovascular events.
@en
prefLabel
Clinical use of high sensitivi ...... adverse cardiovascular events.
@ast
Clinical use of high sensitivi ...... adverse cardiovascular events.
@en
P1476
Clinical use of high sensitivi ...... adverse cardiovascular events.
@en
P2093
José L Torres
Paul M Ridker
P304
P356
10.1097/00001573-200311000-00008
P577
2003-11-01T00:00:00Z